Kiniksa Pharmaceuticals International (MEX:KNSAN) 14-Day RSI: N/A (As of Sep. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:KNSAN Kiniksa Pharmaceuticals International PLC MEX:KNSAN
50 GF Score
Price MXN754.37
GF Value MXN549.40
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2026-09-12), Kiniksa Pharmaceuticals International's 14-Day RSI is N/A.

The industry rank for Kiniksa Pharmaceuticals International's 14-Day RSI or its related term are showing as below:

MEX:KNSAN's 14-Day RSI is not ranked *
in the Drug Manufacturers industry.
Industry Median: 46.38
* Ranked among companies with meaningful 14-Day RSI only.

Kiniksa Pharmaceuticals International  (MEX:KNSAN) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Kiniksa Pharmaceuticals International 14-Day RSI Related Terms


MEX:KNSAN vs AMRX, LQDA, LNTH: 14-Day RSI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiniksa Pharmaceuticals International 14-Day RSI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Kiniksa Pharmaceuticals International's 14-Day RSI falls into.


MEX:KNSAN
50GF Score
Kiniksa Pharmaceuticals International PLC MEX:KNSAN
14-Day RSI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiniksa Pharmaceuticals International  (MEX:KNSAN) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Kiniksa Pharmaceuticals International (MEX:KNSAN) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of MXN754.37 is trading 37.3% above its estimated GF Value™ of MXN549.40.

Key valuation signals for MEX:KNSAN:

  • 14-Day RSI: N/A
  • GF Value™: MXN549.40 vs. price of MXN754.37 (37.3% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the MEX:KNSAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kiniksa Pharmaceuticals International Business Description

Other Exchanges KNSA:USA
Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
50GF Score

Get the complete analysis for MEX:KNSAN

14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN754.37
Price
MXN549.40
GF Value